About us

Our team

Experts in developing gene therapies for inherited retinal disorders

AAVantgarde Bio, based in Milan, is developing gene therapies for inherited retinal disorders. The founder, Professor Alberto Auricchio, is a highly recognized scientist and a pioneer in the field of gene therapy.

The company’s technology builds on existing AAV, or adeno-associated virus-based platforms, which are the main viral vector technology used in gene therapy applications. The company is a spin-off of TIGEM, an international research institute based in Naples that is owned and managed by the Telethon Foundation.

Our team

Natalia Misciattelli PhD

Chief Executive Officer

Prof. Alberto Auricchio

Founder and Chief Science Officer

Naveed Shams MD, PhD

Chief Development and Medical Officer

Nina Kotsopoulou PhD

Chief Technical Officer

Mike Murtagh

Senior Vice President Regulatory

Magda Blanco PhD, MBA

Head of Corporate Development

Board of directors

Natalia Misciattelli PhD

Chief Executive Officer

Mr. Mike Heffernan

Chairman

Paola Pozzi

Non-Executive Director (Sofinnova Telethon Fund)

Dr. Ram Palanki

Non-executive Director

Jason Rhodes

Non-Executive Director (Atlas Venture)

Dmitrij Hristodorov

Non-Executive Director (Forbion)

David Steinberg

Non-Executive Director (Longwood Fund)

Doug Kerr

Non-Executive Director (Generation Bio)

Peter Kaiser

Non-Executive Director